Condition: Desmoid-Type Fibromatosis · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.
This description comes directly from the study's public registry record.
Chiara Colombo, MD, Surgical Oncologist · +390223902740 · chiara.colombo@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| IRCCS Istituto di Candiolo Fondazione del Piemonte per l'Oncologia | Candiolo, Italy | Not Yet Recruiting |
| Azienda Ospedaliero Universitaria Careggi | Florence, Italy | Not Yet Recruiting |
| Azienda Usl Toscana centro | Florence, Italy | Not Yet Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
| IRCCS Istituto Oncologico Veneto IOV | Padova, Italy | Not Yet Recruiting |
| Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" | Palermo, Italy | Not Yet Recruiting |
| Università Campus Bio-Medico | Rome, Italy | Not Yet Recruiting |
| Erasmus University Medical Centre | Rotterdam, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07496242